Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=5&sort=-award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=6&sort=-award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-award_amount" }, "data": [ { "type": "Grant", "id": "7686", "attributes": { "award_id": "75N91019D00024-0-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 25810387, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "9023", "attributes": { "award_id": "75N91019D00024-P00004-759102000010-1", "title": "The Adaptive COVID-19 Treatment Trial (ACTT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-03", "end_date": "2025-04-02", "award_amount": 25075500, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.", "keywords": [ "Antiviral Agents", "COVID-19", "COVID-19 therapeutics", "COVID-19 treatment", "Investigation", "Randomized Controlled Clinical Trials", "Safety", "therapeutic evaluation", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "14652", "attributes": { "award_id": "2321666", "title": "PDB Management by The Research Collaboratory for Structural Bioinformatics", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "SABI: Sustained Availability o" ], "program_reference_codes": [], "program_officials": [ { "id": 3188, "first_name": "Steven", "last_name": "Ellis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-01", "end_date": null, "award_amount": 25000000, "principal_investigator": { "id": 7752, "first_name": "Stephen", "last_name": "Burley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 218, "ror": "", "name": "Rutgers University New Brunswick", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 218, "ror": "", "name": "Rutgers University New Brunswick", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "Support from this award will provide ongoing support for the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). The RCSB PDB works with community stakeholders to preserve and deliver rigorously validated, expertly biocurated three-dimensional (3D) biostructure information archived in the Protein Data Bank (hereafter PDB or the archive) to millions of PDB Data Consumers worldwide at no charge and with no limitations on usage. Exploration of these experimentally-determined structures of proteins and nucleic acids via RCSB PDB web portals is enabled by state-of-the-art data analysis, visualization, and download tools. RCSB PDB ensures that structural biology data are Findable-Accessible-Interoperable-Reusable (FAIR). Access to PDB data and RCSB PDB Services will continue to drive patent applications, drug discovery and development, publication of innovative research in scientific disciplines ranging from Agriculture to Zoology, and innovations leading to discovery and development of life-changing biopharmaceutical products and formation of new US companies. Open access to PDB data and RCSB.org tools will help researchers in the fight against pandemics such as COVID-19 and other emerging infectious diseases. RCSB PDB training, outreach, and education efforts leverage PDB data and RCSB PDB staff expertise to develop materials that help students and researchers learn how to connect 3D biostructures to knowledge. Online Training resources and in-person events will enable education of senior undergraduates, graduate students, postdocs, and researchers in academe, government laboratories, and industry, and help to build a robust STEM workforce.<br/><br/>The RCSB PDB research-focused web portal will provide open access to >200,000 experimentally-determined PDB structures, >1,000,000 Computed Structure Models, and a growing number of Integrative/Hybrid structures, making it the only one-stop shop that delivers public domain 3D structure information traversing length scales ranging from small-molecule ligands to small proteins and nucleic acids to enormous macromolecular machines. The intellectual merit of the RCSB Protein Data Bank (PDB) proposal is reflected in the organization’s long history of scientific and technical leadership in sustaining an open-access global data resource that is central to research and education in biology and medicine, by curating, integrating, and disseminating 3D biostructure information in the context of biological function, biochemical pathways cellular processes, disease states, and molecular evolution. RCSB PDB websites supporting research (RCSB.org) and training (PDB-101 website) foster understanding of fundamental biology, biomedicine, and energy in three-dimensions at the atomic level. Efficient, ongoing fulfillment of the RCSB PDB mission has depended critically on extensive collaborations and partnerships with PDB Depositors and Data Consumers, chemical and biological data resources, international leaders in biomolecular data curation, scientific and professional societies, and stakeholder groups with interests in the life sciences, chemistry, computational sciences, medical sciences, drug discovery, biotechnology, and education. Together with this dynamic and evolving network of collaborators, RCSB PDB is committed to delivering data and related cyberinfrastructure services, and providing significant value to diverse user communities in the US and around the globe.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6403", "attributes": { "award_id": "1S10AI160636-01", "title": "Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21534, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-25", "end_date": "2022-07-31", "award_amount": 24903100, "principal_investigator": { "id": 21535, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Planned COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24 months. The trial participants will be selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials will need to interact with trial participants during regular visits as well as conducting in-person assessments of all vaccine trial participants with symptoms that could be due to COVID-19 disease. This will result in close contact between study staff and high-risk participants or infected participants. As a result, study staff need to access a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, as well as the ability to sanitize hands frequently. This combination of PPE will be used during all risky interactions with study participants, such as during nasal swab collection and during evaluation of participants for possible study endpoints, including symptomatic COVID-19 disease. In addition, all staff will need to wear surgical face masks during and throughout their normal workday in the health care setting or on site for mobile study satellite sites. Without appropriate PPE, health care workers are vulnerable to infection with COVID-19, as well as passively transmitting to persons with whom they are in close physical contact. Access to adequate PPE is a critical component of the safe and effective conduct of COVID-19 vaccine trials, and will enable accurate determination of the study endpoints, especially symptomatic COVID- 19 disease.", "keywords": [ "COVID-19", "COVID-19 vaccine", "Clinical Research", "Clinical Treatment", "Clinical Trials", "Collection", "Communities", "Disease", "Enrollment", "Equipment", "Evaluation", "Face", "Goggles", "Hand", "Health Personnel", "Infection", "Masks", "Nose", "Operative Surgical Procedures", "Participant", "Persons", "Resources", "Risk", "Site", "Swab", "Symptoms", "Vaccines", "Visit", "base", "face mask", "health care settings", "high risk", "screening", "transmission process", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "9169", "attributes": { "award_id": "75N92020C00015-P00001-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-28", "end_date": "2021-08-27", "award_amount": 24369230, "principal_investigator": { "id": 24932, "first_name": "STUART HELLYAR HELLYAR", "last_name": "HELLYAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A battery powered, POC/at home device for the quantitation and detection of SARS-CoV-2 simultaneously with Influenza A & B, with the accuracy, specificity and sensitivity equivalent to or better than the current CDC RT-PCR Lab based methodology.", "keywords": [ "COVID-19 detection", "Centers for Disease Control and Prevention (U.S.)", "Devices", "Home", "Influenza A virus", "Influenza B Virus", "Methodology", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Sensitivity and Specificity", "base", "programs" ], "approved": true } }, { "type": "Grant", "id": "8222", "attributes": { "award_id": "75N92021C00008-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-02", "end_date": "2022-04-01", "award_amount": 24361759, "principal_investigator": { "id": 24054, "first_name": "HANJOON", "last_name": "RYU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving confidence in POC tests. Developed over a 6+ year timeframe, the technological differentiation is in the detection core, where Qorvo has optimized the BAW device that is made at low cost and high volume (millions per day for cell phones) for liquid biosensing. Detection of SARS-CoV-2 antigen occurs with a shift in the biosensor resonance frequency as antigen (Nucleocapsid and Spike S1) protein mass accumulates at specific probes on the sensor surface. Traditional optical/ fluorescence sensing is replaced by high-sensitivity, high-specificity solid-state mass-based sensing. While this proposal is focused on antigen test development, Qorvo has submitted for a SARS-CoV-2 IgG antibody test EUA on the same BAW platform that was completed in less than 10 weeks with world-class performance of 100% specificity and 100% negative cross reactivity. Given this is just one of over a dozen other assays previously run through this platform, the results give us extreme confidence in our ability to execute the viral antigen technical and timeline tasks. Qorvo has invested heavily in manufacturing infrastructure commercial development for the antibody test as well as existing veterinary and human development products so the antigen will be part of a product suite. RADx assistance will enable acceleration of regulatory and US-based high-volume manufacturing ramp.", "keywords": [ "2019-nCoV", "Acceleration", "Acoustics", "Antigens", "Biological Assay", "Biosensing Techniques", "Biosensor", "Cellular Phone", "Contracts", "Detection", "Development", "Devices", "Fluorescence", "Frequencies", "Human Development", "Immunoglobulin G", "Infrastructure", "Investigation", "Liquid substance", "Nucleocapsid", "Optics", "Performance", "Production", "Proteins", "RADx", "RADx Tech", "Ramp", "Running", "SARS-CoV-2 antigen", "Secure", "Specificity", "Surface", "System", "TimeLine", "Viral Antigens", "antibody test", "antigen test", "base", "cost", "cross reactivity", "design", "detection platform", "improved", "point of care", "point of care testing", "product development", "sensor", "solid state" ], "approved": true } }, { "type": "Grant", "id": "9039", "attributes": { "award_id": "75N91019D00024-P00002-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 24161705, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Coronavirus", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "9226", "attributes": { "award_id": "75N92020C00034-P00001-9999-1", "title": "RADX-TECH - ELLUME USA, LLC COVID-19 ANTIGEN TEST FOR THE DIRECT DETECTION OF THE SARS COV-2 VIRUS.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 21470000, "principal_investigator": { "id": 24967, "first_name": "SCOTT", "last_name": "FRY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A point-of-care, in vitro diagnostic test for the detection of an acute COVID 19 infection for use by healthcare professionals. The test will detect the nucleoprotein antigen of the SARS-CoV-2 virus from a healthcare provider-collected mid-turbinate nasal swab using a hand-held digital platform. The test system is connected to a cloud platform to provide real time access to patient test results by public health authorities for surveillance and monitoring. The test system includes: 1) a single-use test cartridge that connects to the hand-held digital platform 2) a sample collection and processing device 3) a squeezable vial containing a fixed volume of extraction fluid 4) ellume.lab, a hand-held digital platform designed to display test results and provide connectivity to Ellume's cloud. 5) a cloud database and interface for real time data collection, analytics and sharing The test is based on Ellume's established fluorescent immunoassay cartridge with digital detection technology, and leverages a proprietary fluorescence biosensor, with a light signature produced by quantum dot nanoparticles detected and digitized by a highly sensitive but fully disposable optoelectronics package. Ellume.lab, Ellume's digital platform, is a hand-held smart device that can read 2 test cartridges at a time. The device provides a digital user interface and includes step-by-step test instructions, digital interpretation of test results, and is connected to Ellume's cloud platform. The device also connects to the clinic's electronic medical record (EMR) system. The device requires no calibration or maintenance, and is battery operated with over 24 hours use before requiring charging.", "keywords": [ "Acute", "Biosensor", "COVID-19 detection", "Calibration", "Charge", "Clinic", "Computerized Medical Record", "Data Collection", "Databases", "Detection", "Devices", "Fluorescence", "Hand", "Health Personnel", "Health Professional", "Hour", "Immunoassay", "Instruction", "Light", "Liquid substance", "Maintenance", "Monitor", "Nasal turbinate bone structure", "Nucleoproteins", "Patients", "Public Health", "Quantum Dots", "RADx Tech", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Step Tests", "System", "Technology", "Test Result", "Testing", "Time", "Vial device", "Virus", "antigen test", "authority", "base", "cloud platform", "design", "detection test", "digital", "in-vitro diagnostics", "nanoparticle", "nasal swab", "point of care", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "9363", "attributes": { "award_id": "1S10AI162059-01", "title": "Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6245, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-11-05", "end_date": "2022-10-31", "award_amount": 21360749, "principal_investigator": { "id": 6247, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Planned COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24 months. The trial participants will be selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials will need to interact with trial participants during regular visits as well as conducting in-person assessments of all vaccine trial participants with symptoms that could be due to COVID-19 disease. This will result in close contact between study staff and high-risk participants or infected participants. As a result, study staff need to access a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, as well as the ability to sanitize hands frequently. This combination of PPE will be used during all risky interactions with study participants, such as during nasal swab collection and during evaluation of participants for possible study endpoints, including symptomatic COVID-19 disease. In addition, all staff will need to wear surgical face masks during and throughout their normal workday in the health care setting or on site for mobile study satellite sites. Without appropriate PPE, health care workers are vulnerable to infection with COVID-19, as well as passively transmitting to persons with whom they are in close physical contact. Access to adequate PPE is a critical component of the safe and effective conduct of COVID-19 vaccine trials, and will enable accurate determination of the study endpoints, especially symptomatic COVID- 19 disease.", "keywords": [ "COVID-19", "COVID-19 vaccine", "Clinical Research", "Clinical Treatment", "Clinical Trials", "Collection", "Communities", "Disease", "Enrollment", "Evaluation", "Face", "Goggles", "Hand", "Health Personnel", "Infection", "Participant", "Persons", "Resources", "Risk", "SARS-CoV-2 infection", "Site", "Symptoms", "Vaccines", "Visit", "base", "health care settings", "high risk", "nasal swab", "personal protective equipment", "screening", "surgical mask", "symptomatic COVID-19", "transmission process", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "8204", "attributes": { "award_id": "75N92021C00013-0-9999-1", "title": "THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE DELIVERABLE DUE DATES FOR RADX TECH PROJECT 2200", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-16", "end_date": "2022-04-15", "award_amount": 21300000, "principal_investigator": { "id": 24039, "first_name": "WALLY", "last_name": "NARAJOWSKI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Our DASH-HT molecular diagnostic system will detect SARS-CoV-2 RNA in asymptomatic subjects in 12 minutes with a throughput of 30 per hour. Specimens can be nasal or nasopharyngeal swabs. Less than 1 minute of operator time is required to elute specimens in the cartridge and scan barcodes. The cartridge, which is closed after removing the swab, contains all reagents needed for extraction, purification and RT-qPCR. 40 cycles of qPCR are performed in less than 5 minutes after sample prep which takes 7 minutes. Six processing units are housed in a cabinet that contains power and environmental control system so the system can be run outdoors year round. It is small and light enough to be transported as checked luggage on domestic airlines. Cartridges are designed to be stable for at least 1 year at ambient temperatures of 4 to 30 degrees C. They are creditcard sized for high density packaging. Our SARS-CoV-2 RT-qPCR assay has analytical sensitivity of 10 copies, and has been multiplexed with a process control. Alpha prototypes are currently running in CIGHT R&D labs. They are recently-modified versions of a point of care system that has been in development for 3 years. It was scheduled to go into clinical trails with flu A/B and STI panels at the end of this year. While this high-throughput version will immediately fill a critical gap in COVID testing, systems can be scaled down to meet needs of urgent care clinics and doctors offices that may be involved in the future.", "keywords": [ "2019-nCoV", "Bar Codes", "Biological Assay", "COVID testing", "COVID-19 detection", "Clinic", "Clinical", "Development", "Future", "Hour", "Light", "Modification", "Point-of-Care Systems", "Process", "RADx Tech", "RNA", "Reagent", "Running", "Sampling", "Scanning", "Schedule", "Specimen", "Swab", "System", "Temperature", "Time", "Update", "density", "design", "diagnostic platform", "flu", "molecular diagnostics", "nasal swab", "nasopharyngeal swab", "prototype", "research and development", "urgent care" ], "approved": true } } ], "meta": { "pagination": { "page": 5, "pages": 1442, "count": 14420 } } }